Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 07, 2015 3:31 AM ET

Life Sciences Tools and Services

Company Overview of Celerion Inc.

Company Overview

Celerion Inc. provides early clinical pharmacology research services for pharmaceutical and biotechnology companies in the United States and internationally. The company focuses on delivering applied translational medicine to support early drug development decisions. Its services include global clinical research (Phase I and IIa, and NDA-enabling clinical pharmacology study conduct); clinical pharmacology sciences (modeling and simulation, study design and protocol development, clinical data sciences, biostatistics, pharmacokinetics/pharmacodynamics (PK/PD), and medical writing and reporting); global bioanalytical services (discovery to late stage services with capabilities in small and larg...

621 Rose Street

Lincoln, NE 68502

United States

Founded in 2010





Key Executives for Celerion Inc.

Chief Executive officer and President
Age: 62
Chief Financial Officer
Chief Cardiologist and Global Medical Director of Cardiac Safety Services
Vice President of Global Business Development
Vice President of Global Bioanalytical Services
Compensation as of Fiscal Year 2015.

Celerion Inc. Key Developments

Celerion Expands Ophthalmological Capabilities to Patient Populations in Collaboration with Queen's University, Belfast

Celerion, announced the expansion of ophthalmological services in the Belfast, Northern Ireland UK facility, by building on the successful relationship with Queen's University in Belfast. Celerion will expand its collaboration with Queen's University for access to patient populations, specialized procedures and their scientific expertise in this area. This new focus will enable Celerion to apply expertise acquired from several years of performing precise ophthalmologic measurements as part of assessing the safety of new drug candidates. By moving beyond clinical safety assessment, Celerion scientists and colleagues at The Centre for Experimental Medicine at Queen's University can perform assessments of drug effect in a controlled research environment. The focus will be on patients with eye diseases such as diabetic retinopathy, age-related macular degeneration, glaucoma, and retinal vein occlusions.

Celerion Appoints Robert Lester as Chief Cardiologist, Global Medical Director of Cardiac Safety Services

Celerion announced the appointment of Robert Lester MD FACC, as Chief Cardiologist, Global Medical Director of Cardiac Safety Services. Dr. Lester will develop and lead Celerion's strategic vision in Cardiac Safety Services. He will be based in the facility in Phoenix, Arizona. Dr. Lester comes to Celerion with over 25 years experience in clinical medicine and academia, as well as over 13 years experience as a Director and Senior Cardiologist at several Contract Research Organizations (CROs) and ECG Core labs. Dr. Lester will utilize his extensive experience and expertise in the area of cardiac safety, to provide advice and lead client programs. He will also be a driving force for Celerion's innovative Highly Automated ECG Core Lab that enables clients to expedite ECG review, thereby significantly reducing the time and cost for cardiac safety studies over traditional approaches.

Foundation for the National Institutes of Health Selects Celerion to Provide Clinical Recruitment and Conduct to Support the Beta Cell Project

Celerion announced that it has been selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to provide clinical support for The Beta Cell Project. The Beta Cell Project is a program of studies designed to standardize biomarker measures of beta cell function. Celerion will provide clinical recruitment and conduct to support The Beta Cell Project and assist the FNIH in developing pharmacodynamic measures of beta cell function, with the goal to create industry standards.

Similar Private Companies By Industry

Company Name Region
North American Science Associates, Inc. United States
Avelas BioSciences, Inc. United States
MakroCare Clinical Research Limited United States
ImmunoTox, Inc. United States
Comparative Biosciences, Inc. United States

Recent Private Companies Transactions

October 29, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Celerion Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at